drugset / Trial / NCT06942442
A Phase II Trial of Tebentafusp in HLA-A*02:01 Positive Patients With Advanced Clear Cell Sarcoma
Phase 2
Recruiting
47 enrolled
Sarcoma Alliance for Research through Collaboration
Memorial Sloan Kettering Cancer Center · collabRoyal Marsden NHS Foundation Trust · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a multi-center, open label, phase II study of tebentafusp in patients with unresectable or metastatic clear cell sarcoma (CCS).
Timeline
- Start
- 2025-10-22
- Primary completion
- 2030-10-01
- Completion
- 2030-10-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tebentafusp | Protein / enzyme biologic | 68 ug | Intravenous |